Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC plus Toripalimab in Advanced Urothelial Carcinoma
NCT05302284Phase 3Recruiting
- Sponsor
- RemeGen
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin in urothelial carcinoma (UC), sponsored by RemeGen. Started Jun 2022; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05302284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302284.